This event is sponsored by Nutter McClennen and Fish LLP.
By Dan O'Brien, firstname.lastname@example.org
Updated: 04/11/2014 07:00:21 AM EDT
LOWELL -- A medical-device startup developed within UMass Lowell's M2D2 community said this week that it has landed $17 million in equity funding.
InfoBionic Inc., a startup that provides patient monitoring for chronic-disease management, intends to use the funds to pay for the commercialization of its flagship product, the MoMe System, according to CEO Nancy Briefs.
M2D2 in partnership with their sponsors Nutter McClennen & Fish LLP and Smith & Nephew is hosting a medical device startup competition that will find Massachusetts' best new medical device ventures - and award thousands of dollars worth of services.
M2D2 is pleased to announce the M2D2 New Venture Competition 2014 to showcase the innovative developments of early-stage medical device companies. Companies will compete for $50,000 of services from M2D2, Nutter McClennen & Fish LLP, and Smith & Nephew, Inc. See below for description of services.
Who is Eligible
The Massachusetts Medical Device Development Center - M2D2 New
Venture Competition is open to medical device technology-based startup
businesses. Companies developing devices which could impact Orthopedic
Reconstruction, Sports Medicine, and Trauma are particularly encouraged to apply.
The venture must involve the development of a new medical device. Companies
need not be based in Massachusetts to be eligible.
Competition Details and Deadlines
A total of $25,000 in M2D2 Services will be awarded, including:
Product Development (prototyping, etc.)
Business Development (business plans, market development, etc.)
Medical Development (clinician consultation, animal trials, etc.)
M2D2 Laboratory Space
A total of $15,000 in Legal Services from Nutter McClennen & Fish LLP
A total of $10,000 in services from Smith & Nephew, Inc.
Entry Fees - Apply early to receive discounted application fees:
By January 31, 2014: $25
By February 10, 2014: $50
For full contest details, including application please contact Mary Ann Picard by email at email@example.com or by phone at 978-934-3465. Check back again or check our website at www.uml.edu/M2D2 as we will be adding further information regarding the M2D2 New Venture Competition in the coming week!
LOWELL, Mass., Jan. 8, 2014 /PRNewswire/ -- InfoBionic™, an emerging digital health company focused on creating superior patient monitoring solutions for chronic disease management, today announced receipt of CE Mark for the MoMe™ System for cardiac arrhythmia monitoring. The MoMe System is the first universal remote patient monitoring platform with seamless transition between Holter, Event, and Mobile Cardiac Telemetry (MCT) modes. The innovative platform, which leverages Cloud computing and proprietary analytics, is poised to revolutionize the $3B worldwide cardiac monitoring market by delivering on-demand access to patient data for diagnosis.
The MoMe System draws on the recent convergence of medical devices, database analytics, new sensors, and wireless protocols to provide a universal patient monitoring platform complete with real-time, high-quality patient data for improved arrhythmia detection.
"Existing cardiac patient monitoring systems have significant limitations, including poor data quality and limited data availability," stated Liviu Klein, M.D., UCSF Heart and Vascular Center. "The MoMe System provides high-quality data and real-time rhythm history as well as activity, respiration and symptom tracking that allows me to make a fast, accurate, timely and efficient medical diagnosis."
Nancy Briefs, Chief Executive Officer, commented, "We are pleased to receive CE Mark for the MoMe System. We believe the system will transform the arrhythmia monitoring market by offering superior arrhythmia detection and favorable physician practice economics. We look forward to commercializing our first product for cardiac arrhythmia monitoring in early 2014."
InfoBionic™ Inc., an emerging digital health company is dedicated to transforming healthcare delivery by providing anywhere, anytime access to cardiac event monitoring with improved event detection and clinical efficacy through a lower cost business model. The MoMe™ System offers superior remote patient monitoring for chronic diseases with an initial market focus on cardiac arrhythmias.
For more information please visit www.infobionic.com.
SOURCE InfoBionic Inc.